Fourth Omnibus Amendment to Securities Purchase Agreement



 Exhibit 10.7 
 FOURTH OMNIBUS AMENDMENT 
 This FOURTH OMNIBUS AMENDMENT (this
“Fourth Amendment”) is made and entered into as of April 3, 2012, by and among Tang Capital Partners, LP, RTW Investments, LLC, Galena Biopharma, Inc. (formerly RXi Pharmaceuticals Corporation) and RXi Pharmaceuticals
Corporation (formerly RNCS, Inc.). 
 WHEREAS, the parties entered into a Securities Purchase Agreement dated as of
September 24, 2011 (the “Securities Purchase Agreement”) and the Ancillary Agreements related thereto, including the Bridge Notes; 
 WHEREAS, the parties entered into an Omnibus Amendment dated as of February 6, 2012 (the “First Amendment”), a Second Omnibus Amendment dated as of March 5, 2012 (the
“Second Amendment”) and a Third Omnibus Amendment dated as of March 30, 2012 (the “Third Amendment” and, together with the First Amendment and the Second Amendment, the “Previous Amendments”),
amending certain provisions of the Securities Purchase Agreement and the Bridge Notes; 
 WHEREAS, the Securities Purchase
Agreement, as amended by the Previous Amendments, in Section 8.01(c) thereof provides that the Agreement may be terminated by either the Company or the Investors if the Closing has not occurred on or before 5:00 p.m., Eastern Standard Time, on
March 31, 2012, which date may be extended from time to time by mutual written consent of the Company and the Investors; 

WHEREAS, the Bridge Notes dated September 24, 2011 held by the Investors, as amended by the First Amendment, in Section 1.1
thereof each provide for a Maturity Date (as defined in the Bridge Notes) of the earlier of (i) April 4, 2012 or (ii) an Event of Default (as defined in the Bridge Notes); 

WHEREAS, the parties desire to amend such provisions of the Securities Purchase Agreement and the Bridge Notes to extend the
April 4, 2012 date; 
 NOW, THEREFORE, in consideration of the premises and mutual covenants herein, and for other good and
valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows: 
 1.
Securities Purchase Agreement Amendment. Section 8.01(c) of the Securities Purchase Agreement, as amended by the Previous Amendments, is hereby further amended to replace “April 4, 2012” with “April 11, 2012”.

 2. Bridge Notes Amendment. The Bridge Notes, as amended by the Previous Amendments, are hereby further amended to
replace references to “April 4, 2012” with “April 11, 2012”. 
 3. Miscellaneous. Capitalized terms
used herein and not defined shall have the meanings set forth in the Securities Purchase Agreement or in the Bridge Notes, in each case, as amended, as applicable. The terms and conditions set forth in Article X of the Securities Purchase Agreement
are incorporated herein by reference. Nothing herein shall constitute a waiver of any provision of the Securities Purchase Agreement or any of the Ancillary Documents pursuant to Section 10.03 of the Securities Purchase Agreement. 

[Signature Page Follows] 







 IN WITNESS WHEREOF, the parties hereto have executed this Fourth Amendment as of the date
first above written. 
  

			
	GALENA BIOPHARMA, INC.
		
	By:	 	/s/ Mark J. Ahn
		 	 Name: Mark J. Ahn

Title:   President and Chief Executive

            Officer



  

			
	RXi PHARMACEUTICALS CORPORATION
		
	By:	 	/s/ Mark J. Ahn
		 	 Name: Mark J. Ahn
 Title:
  President



  

			
	TANG CAPITAL PARTNERS, LP
		
	By:	 	/s/ Kevin C. Tang
		 	 Name: Kevin C. Tang

Title:   Managing Director



  

			
	RTW INVESTMENTS, LLC
		
	By:	 	/s/ Roderick Wong
		 	 Name: Roderick Wong

Title:   Managing Member



 [Signature Page to Fourth Omnibus Agreement] 

  
 2